Clinical endpoints in allergen immunotherapy: State of the art 2022

R. Gerth van Wijk; L. Klimek; O. Pfaar

doi:10.5414/ALX02334E

Clinical endpoints in allergen immunotherapy: State of the art 2022

R. Gerth van Wijk^*, L. Klimek, O. Pfaar

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Review article › Academic › peer-review

3 Citations (Web of Science)

Abstract

110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clinical trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted outcome measures are available for cost-effectiveness studies.

Original language	English
Pages (from-to)	39-46
Number of pages	9
Journal	Allergologie
Volume	7
Issue number	1
DOIs	https://doi.org/10.5414/ALX02334E
Publication status	Published - Mar 2023

Bibliographical note

Publisher Copyright:
© 2023 Dustri-Verlag Dr. Karl Feistle. All rights reserved.

Access to Document

10.5414/ALX02334E

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012882/pdf/allergologieselect-7-039.pdfLicence: Unspecified

Cite this

@article{b233877bc3d44005925dbed75c4c36d6,

title = "Clinical endpoints in allergen immunotherapy: State of the art 2022",

abstract = "110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clinical trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted outcome measures are available for cost-effectiveness studies.",

author = "{van Wijk}, {R. Gerth} and L. Klimek and O. Pfaar",

year = "2023",

month = mar,

doi = "10.5414/ALX02334E",

language = "English",

volume = "7",

pages = "39--46",

journal = "Allergologie",

issn = "0344-5062",

publisher = "Dustri-Verlag Dr. Karl Feistle",

number = "1",

}

TY - JOUR

T1 - Clinical endpoints in allergen immunotherapy

T2 - State of the art 2022

AU - van Wijk, R. Gerth

AU - Klimek, L.

AU - Pfaar, O.

PY - 2023/3

Y1 - 2023/3

N2 - 110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clinical trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted outcome measures are available for cost-effectiveness studies.

AB - 110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clinical trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted outcome measures are available for cost-effectiveness studies.

UR - http://www.scopus.com/inward/record.url?scp=85150215275&partnerID=8YFLogxK

U2 - 10.5414/ALX02334E

DO - 10.5414/ALX02334E

M3 - Review article

C2 - 36925995

AN - SCOPUS:85150215275

SN - 0344-5062

VL - 7

SP - 39

EP - 46

JO - Allergologie

JF - Allergologie

IS - 1

ER -

Clinical endpoints in allergen immunotherapy: State of the art 2022

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this